Lumen Bioscience, a drug discovery company developing therapies for a range of diseases, raised $30 million in a Series C extension, CEO Brian Finrow tells Axios Pro.
Why it matters: Lumen is fielding significant licensing interest from pharma companies for its C. difficile and weight loss drug candidates, he says.
